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Abstract
Aggregation of alpha-synuclein (ASYN) in Lewy bodies and Lewy neurites is the typical pathological hallmark of Parkinson’s
disease (PD) and other synucleinopathies. Furthermore, mutations in the gene encoding for ASYN are associated with
familial and sporadic forms of PD, suggesting this protein plays a central role in the disease. However, the precise
contribution of ASYN to neuronal dysfunction and death is unclear. There is intense debate about the nature of the toxic
species of ASYN and little is known about the molecular determinants of oligomerization and aggregation of ASYN in the
cell. In order to clarify the effects of different mutations on the propensity of ASYN to oligomerize and aggregate, we
assembled a panel of 19 ASYN variants and compared their behaviour. We found that familial mutants linked to PD (A30P,
E46K, H50Q, G51D and A53T) exhibited identical propensities to oligomerize in living cells, but had distinct abilities to form
inclusions. While the A30P mutant reduced the percentage of cells with inclusions, the E46K mutant had the opposite effect.
Interestingly, artificial proline mutants designed to interfere with the helical structure of the N-terminal domain, showed
increased propensity to form oligomeric species rather than inclusions. Moreover, lysine substitution mutants increased
oligomerization and altered the pattern of aggregation. Altogether, our data shed light into the molecular effects of ASYN
mutations in a cellular context, and established a common ground for the study of genetic and pharmacological modulators
of the aggregation process, opening new perspectives for therapeutic intervention in PD and other synucleinopathies.
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Introduction
Alpha-synuclein (ASYN) is an abundant neuronal protein whose
normal function is still elusive, but seems to be related to SNARE-
complex assembly [1]. Misfolding and aggregation of ASYN in
proteinaceous inclusions, known as Lewy bodies (LBs), are
associated with Parkinson’s disease (PD) and other neurodegen-
erative disorders known as synucleinopathies [2,3]. PD is the
second most common neurodegenerative disease, affecting ap-
proximately 1% of the population over 65 years of age [4], and is
therefore a growing problem in the aging population. Both point
mutations [5,6,7] and multiplications [8,9,10,11] of the SNCA
gene, encoding for ASYN, have been linked to autosomal-
dominant forms of PD. More recently, GWAS studies identified
the SNCA locus as a strong risk factor underlying PD [12,13], and
two additional familial mutations (G51D and H50Q) were recently
identified [14,15,16]. The H50Q mutation is associated with late-
onset parkinsonism, and the patients exhibit similar pathological
features to those observed for patients carrying E46K or A53T
mutations [17]. The G51D mutation is associated with early onset
of disease [15].
Over the years, numerous in vitro and in vivo studies confirmed
the toxic potential of both wild type (WT) and PD-linked ASYN
mutants [18,19]. In vitro, these ASYN mutations alter the
aggregation process and interfere with oligomerization, fibril
formation, and subcellular distribution [20,21,22]. Upon overex-
pression, ASYN induces aggregation and cytotoxicity [23],
disrupts vesicular transport [24,25], causes mitochondrial deficits,
impairs autophagy [26], increases sensitivity to oxidative stress
[27], impairs vesicle recycling, neuronal plasticity and synaptic
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integrity [28] as well as the folding/refolding of SNARE proteins
[29]. Several animal models have also been generated based on
the overexpression of either wild type or mutant ASYN, but the
phenotypes reported are quite diverse [30,31,32].
Posttranslational modifications (PTM) in the context of PD are
also controversial. The majority of ASYN in LBs isolated from PD
patients is phosphorylated at serine-129 (S129) but whether this is
a cause or a consequence of aggregation is unclear [33,34,35].
Other ASYN residues like serine-87 (S87) and tyrosines-125, -133
and -136 (Y125, Y133 and Y136) can be also phosphorylated [36].
SUMOylation, another type of PTM that modulates protein-
protein interactions, affects subcellular localization, stability and
solubility of target proteins [37,38]. Engineered mutants of ASYN
to prevent SUMOylation enhanced the tendency to aggregate in
cell-based assays and increase cytotoxicity in dopaminergic
neurons of the substantia nigra (SN), in vivo [38].
Although aggregation of ASYN is recognized as a central
process in synucleinopathies, it is still unclear whether inclusions
are toxic or protective [39]. Actually, accumulating evidence
suggests ASYN oligomers may constitute the toxic species, rather
than mature aggregates [40,41]. To overcome these limitations,
engineered mutation is a simple way to understand the putative
effects impact of determine residues in the context of PD. Several
artificial proline mutants of ASYN (A56P, A30P/A76P double
mutant, and A30P/A56P/A76P triple mutant (TP) display
impaired propensity to fibrilize [40]. A similar effect was reported
for mutants disrupting the formation of salt bridges between b-
strands of ASYN (E35K and E57K) [41], which increases the
formation of oligomers when compared with WT ASYN.
Nevertheless, conflicting results obtained in different cell and
animal models, and the limited existence of systematic studies
comparing the behaviour of WT and ASYN mutants in the same
model systems, complicate our understanding of the molecular
determinants of ASYN aggregation and toxicity. Here, we
conducted a systematic comparison of the effects of PD-linked
and engineered ASYN mutants in two established cell-based
models of ASYN oligomerization [42] and aggregation [43]. Our
findings establish the effects of the different mutants studied and
pave the way for the identification of genetic and pharmacological
modulators of the various processes studied, opening new
perspectives for the design of therapeutic strategies aimed at
targeting specific steps of the ASYN aggregation process.
Results
Design and generation of ASYN mutants
To investigate the molecular determinants of ASYN oligomer-
ization and aggregation in a cellular context, we used site-directed
mutagenesis to generate a panel of 19 ASYN point mutants
including five mutations associated with familial PD (A30P, E46K,
H50Q, G51D and A53T) and others known to interfere with
different aspects of ASYN biology (Fig. 1 and Table S1). Then, we
analysed the behaviour of each mutant in established paradigms of
ASYN oligomerization (Fig. 2A) or aggregation (Fig. 3A).
Effect of mutations on ASYN oligomerization
In order to assess the effect of ASYN mutations on oligomer-
ization, we used a variant of the Bimolecular Fluorescence
Complementation (BiFC) assay we previously described [42],
based on the reconstitution of functional Venus fluorescent protein
promoted by the interaction between, at least, two ASYN
molecules, that enables us to directly visualize the formation of
ASYN dimeric/oligomeric species (hereforth referred to as
oligomeric species for simplicity) in living cells (Fig. 2A) [42]. We
have previously demonstrated that the efficiency of the ASYN
BiFC assay is identical in different cell lines, including HEK cells
[42]. Using epifluorescence microscopy we found that, as
expected, all the ASYN variants formed oligomers in HEK cells
Figure 1. Human ASYN. Scheme representing the structure of human ASYN with the three distinct domains (N-terminal, NAC and C-terminal).
Amino acid residues are indicated in the bottom. Brown bars inside protein domains represent the imperfect hexameric KTKEGV repeats. Arrows
indicate the sites of phosphorylation and the broken lines show the mutated sites.
doi:10.1371/journal.pgen.1004741.g001
Author Summary
The accumulation of aggregated proteins in the brain is
common across several neurodegenerative disorders. In
Parkinson’s disease (PD), the protein alpha-synuclein
(ASYN) is the major component of aggregates known as
Lewy bodies. It is currently unclear whether protein
aggregates are protective or detrimental for neuronal
function and survival. The present hypothesis is that
smaller aggregated species, known as oligomers, might
constitute the toxic forms of ASYN. Several mutations in
ASYN cause familial forms of PD. In the laboratory,
artificial mutations have been designed to enable the
study of the aggregation process. However, different
studies relied on the use of different model systems,
compromising the interpretation of the effects of the
mutations. Here, we addressed this by (i) assembling a
panel of 19 ASYN variants and (ii) by performing a
systematic comparison of the effects of the mutations in
mammalian cell models. Interestingly, our study enabled
us to correlate oligomerization and aggregation of ASYN
in cells. Altogether, our data shed light into the molecular
determinants of ASYN aggregation, opening novel ave-
nues for the identification of modulators of ASYN
aggregation, which conceal great hopes towards the
development of strategies for therapeutic intervention in
PD and other synucleinopathies.
Effects of ASYN Mutations in Cells Models
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(Fig. 2B and C). One striking observation was that the PD-linked
mutant A53T promoted the strongest increase (,50%) in the
accumulation of ASYN oligomers in the nucleus (Figure 2B and
D).
To compare the extent to which different ASYN variants
promoted oligomerization we used flow cytometry to measure the
fluorescence intensities of cells expressing the different mutants.
We observed an increase in fluorescence intensity for proline and
lysine mutants. This increase was around 16.3% for A56P mutant,
and 16.5% for the TP mutant (Fig. 2C). In the case of A30P/A76P
double mutant (DP) and single A76P mutant we observed a trend
towards an increase in fluorescence intensity, but the increase was
not statistically significant. Likewise, we found a 28.4% increase in
oligomerization for the E35K mutant, and 28.1% for the E57K
mutant. In contrast, we found that the S87E mutant, mimicking
phosphorylation at S87, reduced oligomerization by ,16%. To
investigate whether these effects were explained by differences in
the levels of ASYN, we performed immunoblot analysis. We found
that the levels of VN-ASYN decreased for almost all mutants
(statistically significant for G51D, S129D and S87A) and increased
for H50Q, A30P/A76P and K96R/K102R (Fig. 2E, F). Interest-
ingly, there was no correlation between the levels of the mutants
and the fluorescence signal, suggesting the effects observed were
intimately correlated with the effects of the mutations on
oligomerization, and not due to differences in the levels of
expression of the various ASYN mutants.
Effect of mutations on ASYN aggregation
In parallel, we asked whether the selected mutations altered
ASYN inclusion formation. For this, we took advantage of an
established paradigm of ASYN aggregation based on the co-
expression of SynT and synphilin-1, an ASYN-interacting protein
that is also present in LBs (Fig. 3A) [43]. As previously established,
human neuroglioma cells (H4) were co-transfected with plasmids
encoding each of the SynT variants and synphilin-1 and inclusion
formation was assessed 48 hours post-transfection. Since the
inclusion pattern was heterogeneous, we defined four categories
(cells without inclusions, with ,5 inclusions, with more than 5 and
less than 9 inclusions, or $10 inclusions) in order to obtain a more
precise assessment of the effects of the mutations. For the PD-
linked mutants, we found that A30P increased the percentage of
cells without inclusions to ,70% when compared to WT ASYN.
In contrast, the E46K and G51D mutations dramatically
increased the percentage of cells with inclusions to ,90% and
,80%, respectively (Fig. 3B, C and Fig. S1).
In the case of the proline mutants, we observed that all four
mutants reduced the percentage of cells displaying inclusions
(Fig. 3B, C and Fig. S1).
For the E35K and E57K mutants, the number and the size of
the inclusions varied. Both mutants promoted an increase to ,70–
80% of cells with inclusions (Fig. 3B, C and Fig. S1). While we
predominantly observed the presence of small inclusions with the
E57K mutant, we detected a mix of small and larger inclusions
with the E35K mutant (Fig. 3B).
We also investigated the effect of phosphorylation on ASYN
inclusion formation. For this, we screened mutants that block
(S87A, Y125F, S129A and S129G) or mimic (S87E, Y125D and
S129D) phosphorylation. We found that mimicking phosphoryla-
tion on S87 resulted in a marked decrease in the number of
inclusions per cell, with ,80% of the transfected cells displaying
no inclusions (p,0.01 Fig. 3C, Fig. S1A). No significant effect was
observed with the S87A mutant, suggesting the S87 may normally
exist, at least in our cell model, mostly unphosphorylated. Also, no
significant differences were observed for Y125D, S129A, S129G,
or S129D mutants, when compared to WT SynT. However, we
found the Y125F mutation and SUMOylation-deficient mutant
(K96R/K102R) mutation induced an altered inclusion pattern,
with the accumulation of inclusions of different sizes, similar to
that observed with the lysine mutant.
Immunoblot analysis showed that the levels of ASYN varied
depending on the particular mutant being expressed, but we only
found a significant increase in the levels of the S129G mutant
(Fig. 3D and E). Interestingly, we found a trend towards a
decrease in the levels of mutants that promoted accumulation of
inclusions or changed the size of the inclusions (E46K, E57K and
K96R/K102R).
Based on the results obtained in the oligomerization and
aggregation paradigms, we decided to focus on seven ASYN
mutations (A30P, E46K, A53T, E35K, E57K, TP and Y125F)
that had the most pronounced effects for subsequent analysis
(Table S2 and Fig. 4). We examined these selected ASYN mutants
using different assays, including toxicity measurements, biochem-
ical analysis of ASYN, ASYN secretion, degradation pathways,
and Golgi and ER stress (Fig. 4), in order to obtain detailed
information on the cellular effects of specific types of ASYN
accumulations.
ASYN toxicity and aggregation in yeast
We started by investigating the toxicity of the selected variants
of ASYN by taking advantage of the budding yeast as a model of
synucleinopathies, as previously described [23,44]. In conditions
where the expression of ASYN was induced, using galactose-
containing media, we found that almost all mutations induced
toxicity similar to WT ASYN (Fig. 5A). In line with the
observation in H4 cells, the TP mutant did not form inclusions
and the A30P mutant strongly impaired inclusion formation
(Fig. 3B-C and 5B-C). Neither of these mutants was toxic in yeast
(Fig. 5A) [23,44]. Importantly, we found no significant differences
in the levels of expression of all variants tested, ruling out the
possibility that toxicity and/or inclusion formation were due to
differences in the levels of expression of ASYN (Fig. 5D).
Characterization of ASYN species
To further assess the biochemical nature of the ASYN species
visualized by the BiFC assay, we employed non-denaturing
polyacrylamide gel electrophoresis (native-PAGE). Immunoblot
analysis showed a smear, which is indicative of the accumulation
of oligomeric species of various sizes (Fig. 6A).
Figure 2. Mutations effect on ASYN oligomerization. A. Schematic representation of Bimolecular Fluorescence Complementation
assay (BiFC). ASYN BiFC constructs in anti-parallel orientation. B. Representative pictures of ASYN oligomerization. HEK-293 cells
overexpressing VN-ASYN and ASYN-VC constructs. The green fluorescence results from the reconstitution of the Venus fluorophore, promoted by the
interaction of the proteins of interest. Scale bar: 10 mm. C. Oligomerization efficiency. Mean fluorescence intensity of cells expressing different
ASYN mutants was assessed 24 hours post-transfection, using a microcapillary system (GuavaeasyCyte HT system). For each sample 25,000 events
were counted. D. Intracellular distribution of oligomeric ASYN. Nuclear and cytoplasmic venus fluorescence intensities in HEK-293 cells were
quantified using ImageJ. The graph demonstrates an increase in nuclear fluorescence in cells expressing ASYN mutants. For each experiment.25
cells were analysed. E-F. Levels of ASYN. E. Representative immunoblot showing the expression levels of ASYN. F. Immunoblot analysis of the
expression levels of VN-ASYN and ASYN-VC from all the mutations studied in HEK-293 cells. Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n = 3.
doi:10.1371/journal.pgen.1004741.g002
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In order to characterize the structure of the ASYN inclusions
formed in H4 cells, we used stimulated emission depletion (STED)
super resolution microscopy (Fig. 6B). STED provided unprece-
dented access to the fine structure of the ASYN inclusions in the
cytoplasm. We focused on selected mutants that displayed extreme
patterns of aggregation (Fig. 3) and found that both smaller and
larger inclusions are highly compact. For the TP mutant, only
diffuse signal was detected, confirming the inability of this mutant
to accumulate in inclusions that can be resolved by light
microscopy techniques (Fig.6B).
It is widely established that LBs are primarily composed of
amyloid filaments of ASYN [2]. To determine whether the
inclusions formed by the different ASYN mutants were composed
of amyloid-like fibrils, we used thioflavin S (thioS), a dye that binds
specifically to amyloid-like structures [26,45]. We verified that
large inclusions formed by WT or mutant ASYN stained positive
for thioS, whereas small inclusions did not (Fig. 6C). Also, thioS
stained the inner part of the inclusions (marked with arrow head)
(Fig. 6C), suggesting the accumulation of mature amyloid-like
structures in the inner part of the inclusions. To further
characterize these different types of ASYN aggregates, we assessed
the detergent solubility of the inclusions formed by the selected
ASYN mutants. Interestingly, we observed that TP and E57K
accumulated a smaller fraction of Triton X-100 insoluble ASYN
species (Fig. 6D and E).
Intra- and extracellular partitioning of ASYN oligomers
To assess the effect of the selected mutations on the distribution
of ASYN oligomers inside and outside cells, we used a previously
described bioluminescent protein complementation assay (bPCA)
that enables the detection of oligomeric species with great
sensitivity [46]. In this assay, reconstitution of Gaussia princeps
luciferase activity upon ASYN oligomerization was used as a
readout [47] (Fig. 7A). Consistent with the results obtained with
the Venus-based BiFC assay (Fig. 2A), we detected reconstitution
of luciferase activity with all mutants tested. However, we
observed a strong increase in intracellular (Fig. 7B) and
extracellular (Fig. 7C) luciferase activity with the TP and
Y125F ASYN mutants when compared to WT ASYN. This
indicates that not only these mutations are able to promote
increased formation of oligomers inside cells, but also in the
extracellular space.
To determine if these mutants also promoted the release of
oligomeric species we calculated the ratio of luciferase activity in
the media compared to that in cells. Interestingly, we found that
familiar mutants A30P and A53T showed an increased ratio of
luciferase activity outside versus inside cells suggesting that these
mutants also promote the secretion of ASYN oligomers (Fig. 7D).
We confirmed these differences were not simply due to the
accumulation of increased levels of mutant ASYN, since the levels
of expression were identical for all mutants tested (Fig. 7E-F).
Figure 3. ASYN mutation effects in the inclusion formation. A. Constructs used in the aggregation model. This model consists of co-
expressing SynT together with synphilin-1. B. Inclusion pattern in H4 cells. Different SynT mutants resulted in the formation of distinct inclusion
formation in human H4 cells. Scale bar: 10 mm. C. Inclusion quantification. 50 cells were scored per experiment and classified in different groups
according to the pattern of inclusions. Representative cells were drawn to show type of inclusions present in each categories. Lysine mutants (E35K,
E57K) increase the percentage of cells with inclusions and the number of inclusions per cell, whereas A30P and proline mutants reduce percentage of
cells with inclusions and also the number of inclusions per cell. D-E. Levels of ASYN. Immunoblot analysis of the expression levels of ASYN.
Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n = 3.
doi:10.1371/journal.pgen.1004741.g003
Figure 4. Experimental design. WT and ASYN mutants were subjected to a variety of assays as depicted in the schematic.
doi:10.1371/journal.pgen.1004741.g004
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ASYN secretion is inversely correlated with toxicity
ASYN is a cytosolic protein, but recent studies detected both
monomeric and oligomeric forms of ASYN in human cerebrospi-
nal fluid and plasma at low nanomolar concentrations, in both PD
and control individuals [48,49].
To complement the observations with the bioluminescence
complementation assay, we asked whether the selected ASYN
mutants were differentially released from cells using the aggrega-
tion paradigm described above (Fig. 3A). In this case, we
measured the levels of ASYN in the culture medium using a
highly sensitive electrochemiluminescence-based immunoassay
[50]. We detected extracellular ASYN with all variants tested
(Fig 8A).
Next, to demonstrate that the release of ASYN was not caused
by membrane leakage from unhealthy or dying cells, we
performed LDH toxicity measurements in the same media. In
fact, in the aggregation paradigm, we observed an inverse
correlation between ASYN release and cytotoxicity, where the
TP and Y125F mutants appeared as the most toxic forms (Fig. 8B
and C).
Effect of ASYN mutants on lysosomal degradation
Knowing that ASYN is predominantly degraded by lysosomal
pathways and, therefore, requires intact lysosomal function, we
used lysosomal associated membrane protein 1 (LAMP-1) as a
marker to establish the relationship with aggregation formation.
We observed that LAMP-1 partially co-localized with ASYN
inclusions (Fig. 9A), suggesting that at least some types of
inclusions might be degraded in lysosomes. Interestingly, we
observed that some inclusions formed by two of the mutations that
primarily accumulated thioS-negative inclusions (E57K and
Y125F, Fig. 6B) stained positive for LAMP-1 at the periphery
(Fig. 9B), reinforcing the idea that specific types of ASYN
inclusions are degraded in lysosomes.
Golgi fragmentation and ER stress
Given that fragmentation of Golgi apparatus (GA) has been
described in several neurodegenerative diseases [51,52,53], we
next investigated the cellular consequences of the accumulation of
ASYN oligomers or inclusions on this organelle. For this, we
examined the morphological integrity of the GA using fluores-
cence microscopy of cells immunostained for Giantin, an
endogenous transmembrane protein of the cis and medial Golgi
complex (Fig. 10). We defined three types of Golgi structures (non-
fragmented, diffuse and fragmented). In general, we observed that
in the ASYN oligomerization model there was an increased
percentage of cells displaying fragmented Golgi, in comparison to
what was observed in the aggregation model (Fig.10 A-B and Fig.
S2). In particular, we found a statistically significant increase in the
percentage of cells displaying fragmentation of the GA for the
Figure 5. High-copy expression of a-synuclein-GFP variants in yeast. A. Yeast cells expressing GAL1-driven ASYN-GFP variants from 2 m
plasmids were spotted in 10-fold dilutions on selection plates containing 2% glucose (control) or 2% galactose. After incubation for 3 days at 30uC the
plates were photographed. Expression of GFP from the same promoter was used as a control. B. Live-cell fluorescence microscopy of yeast
cells expressing ASYN-GFP. Yeast cells, pre-grown to mid-log phase, were induced in galactose-containing medium and examined for aggregates
at 6 hours of induction. GFP-expressing cells were used as control. Scale bar: 1 mM. C. Aggregate quantification of yeast cells, expressing
ASYN-GFP. For each strain, the number of cells displaying cytoplasmic foci is presented as percent of the total number of cells counted. For
quantification of aggregation at least 300 cells were counted per strain and per experiment. GFP-expressing cells were used as a control. Student’s t
test (*p,0.05, **p,0.01, ***p,0.001). D. Protein levels of ASYN-GFP variants. Expression of ASYN-GFP variants was induced for 6 hours in
galactose-containing medium. Equal amounts of crude protein extracts were used for Western analysis with anti-ASYN antibody and anti-cdc28
antibody as a loading control. n = 2.
doi:10.1371/journal.pgen.1004741.g005
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E35K and E57K mutants (Fig. 10A and Fig. S2A). In the ASYN
aggregation paradigm, the GA displayed normal compact
morphology near the nucleus (Fig. 10B and Fig. S2B).
Recent studies showed that endoplasmic reticulum (ER) stress,
together with deficient protein degradation, plays a crucial role in
the death of dopaminergic cells [54]. Under ER stress conditions,
BiP is upregulated and preferentially binds to misfolded proteins in
the ER [55]. We observed that oligomeric forms of ASYN
promoted an increase in the levels of BiP (E46K and A53T
mutants)(Fig.10C and D) whereas no differences were detected in
the aggregation paradigm (Fig.10 E).
Taken together, these results suggest oligomeric forms of ASYN
are more capable of promoting Golgi fragmentation and ER stress
than aggregated forms.
Effect of mutations on ASYN phosphorylation
Accumulating evidence implicates phosphorylation on ASYN
aggregation and toxicity [56]. However, it is unclear whether
mutations in ASYN affect the typical pattern of phosphorylation.
Using the oligomerization assay, we investigated whether ASYN
was differentially phosphorylated on S129 (Fig. S3). Interestingly,
we detected a significant increase in S129 phosphorylation in the
E35K mutant, and only a trend towards an increase for the
familial mutants and E57K (Fig. S3). The results shows that
phosphorylation of ASYN on S129 is altered in the context of
specific mutations known to affect the aggregation of the protein.
Discussion
Given the central role of ASYN in PD and other synucleino-
pathies, and the uncertainty about the precise molecular
mechanisms leading to neurodegeneration, we sought to take
advantage of various cellular systems in order to systematically
compare a set of ASYN mutants according to their effects on
different cell functions.
Our systematic analysis enabled us to directly compare the
effects of the selected mutations in terms of oligomerization and
aggregation (Fig. 11). We observed that all 19 mutations tested
enabled the formation of ASYN oligomers, as assessed by the BiFC
system and biochemical methods. Interestingly, we found the
different mutants resulted in the accumulation of different types of
inclusions.
While we did not detect significant differences in the oligomer-
ization induced by familial PD mutations, the A30P mutant
displayed a reduced propensity to form inclusions, in contrast to
the E46K and G51D mutants, which enhanced inclusion
formation when compared with WT ASYN. The fact that we
observed a decrease in the number of inclusions with the A30P
might be related to the long-range contacts between the N and C-
termini, shielding the central domain, which is known to promote
aggregation, and reducing the formation of the same types of
inclusions observed with WT or other mutants. On the other
hand, the robust increase of inclusion formation observed with the
E46K mutant might be due to the location of the mutation within
the KTKEGV repeats that are involved in alpha-helix formation
[57]. The charge difference introduced by the mutation could
enhance the destabilization of the protein structure, leading to an
increased propensity to aggregate, as reported previously [57].
Recent studies showed that the G51D mutation attenuates aSyn
aggregation in vitro [58,59]. However, we observed a different
trend in our cell models, where G51D increased the number of
aSyn inclusions per cell, as observed with the E46K mutant. This
might be explained by differences in the cellular environment in
the different models, but might also be due to the presence of
synphilin-1 in the particular model we used for aSyn aggregation.
The same might apply to the H50Q mutant since, in contrast to
other studies, we did not observe any difference in comparison to
WT aSyn [59]. For the A53T mutant we found increased presence
of oligomeric species in the nucleus, but no differences in terms of
the aggregation pattern. Thus, additional studies on the effect of
ASYN in the nucleus will be important.
The use of engineered mutants enables the exploration of the
structural determinants of ASYN physiology in the cell. Artificial
proline mutations were designed to impair fibrillization in vitro
and promote the formation of soluble oligomers [40]. Indeed, in
our cell models, the proline mutants resulted in increased
oligomerization (Fig. 2B and C) and lowered the propensity to
form inclusions. In particular, the TP mutant increased oligomer-
ization as assessed by BiFC and bPCA, and reduced inclusion
formation. These observations were also confirmed in yeast cells,
where the A30P formed fewer inclusions, and the TP mutant
completely blocked inclusion formation. However, in contrast to
what was observed in primary neurons, worms, and in flies [40],
the proline mutants failed to promote increased cytotoxicity in
yeast cells. One possibility is that yeast process the species formed
by the proline mutants in a distinct manner, explaining the lower
levels of toxicity.
The lysine mutants (E35K and E57K) were designed to disrupt
salt bridges between the b-strands of ASYN and to interfere with
its binding to lipid membranes [41]. We found both mutants
increased ASYN oligomerization and promoted distinct inclusion
patterns. The lack of thioS staining suggests the inclusions may
represent either off-pathway or immature species that cannot
proceed towards the formation of mature amyloid-like inclusions.
Interestingly, in cells where we could detect inclusions formed by
the E57K mutant, these appeared surrounded by LAMP1,
suggesting they were targeted to lysosomal degradation.
Post-translational modifications (PTMs) are important modula-
tors of the structural and functional properties of proteins in health
and pathological conditions. Several lines of evidence suggest that
phosphorylation of ASYN may play an important role in
regulating its aggregation, fibrillogenesis, Lewy body formation,
and neurotoxicity in vivo. In addition, it appears that, in vivo, less
than 5% of ASYN is normally phosphorylated [60] and that this
occurs predominantly in the C-terminus (S129 and Y125) but also
in the NAC domain (S87). However, there is still no consensus on
the effects of phosphorylation due to existing contradictory results
[56,61,62,63]. S87 is located in the NAC region, which is crucial
for ASYN aggregation and fibrillogenesis [64] and is also the
region involved in interactions with other proteins [62]. Our study
supports the importance the NAC domain in the formation of
ASYN inclusions, as the S87E phosphomimic mutant induced
Figure 6. ASYN biochemical state. A. Native Gels. Immunoblot analysis of native PAGE of cells transfected with the BiFC constructs in HEK 293
cells. Smears indicate the presence of oligomeric species of ASYN with different sizes. n = 2. B. STED microscopy. Selected mutants were imaged in
order to characterize the fine structure of the inclusions. C. Thioflavin S staining. H4 cells expressing selected SynT mutants were incubated with
ThioS in order to reveal beta sheet-rich structures. Some of the inclusions display amyloid-like properties, with increased staining in the inner part of
the inclusions, indicated with arrow heads (c). Scale bar: 10 mm. D-E. Triton X-100 solubility assay and quantification. H4 cells show that all
mutants form detergent insoluble species. Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n = 2. Quantification of insoluble fraction shows a
decrease in TP and E57K mutants.
doi:10.1371/journal.pgen.1004741.g006
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Figure 7. ASYN bPCA. A. Schematic representation of the ASYN bPCA constructs. Non-bioluminescent halves of humanized Gaussia
luciferase (hGLuc) were fused to ASYN monomers. B-C. Intact cells (intracellular) and medium (extracellular) from H4 cells co-transfected with S1 and
S2 were assayed for luciferase activity 48 hours post-transfection. Intracellular (B) and extracellular (C) TP displayed a 3-fold increase in luciferase
activity compared to WT. n = 12. Student’s t test (*p,0.05, **p,0.01, ***p,0.001) D. Ratio of luciferase activity in media compared to cells was
expressed. n = 12, Student’s t test (*p,0.05, **p,0.01, ***p,0.001) E-F. Levels of ASYN. Immunoblot analysis of the expression levels of ASYN
showing similar levels. n = 3.
doi:10.1371/journal.pgen.1004741.g007
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different effects than those observed with the S87A mutant
(Fig. 3B and C). This is in line with in vitro experiments where the
S87E mutant inhibits ASYN aggregation [62]. Again, this effect on
the formation of cytoplasmic inclusions might be attributed to
changes in the conformation when binding to membranes, as
other studies suggested [63]. Moreover, a recent study showed that
S87E ASYN reduces aggregation and is less toxic [62].
Detecting significant levels of Y125-P in ASYN in human brain
tissues has proven difficult [65]. Our results indicate, in the context of
living cells, Y125-P ASYN exhibits similar aggregation properties to
WT ASYN, in accordance with what was observed in other systems
[65]. We also observed the accumulation of small inclusions for the
Y125F mutant that were similar to those formed by the lysine mutants.
Recently, it was shown that when SUMO acceptor sites in ASYN
(K96R/K102R) are modified, SUMOylation is strongly impaired,
leading to increased inclusion formation and toxicity [38]. In our
study, we observed only a 10% increase in the percentage of cells
displaying inclusions and, interestingly, we observed the accumu-
lation of smaller inclusions. These small inclusions promoted by
several mutants tested (E35K, E57K, Y125F and SUMOylation
mutants, Fig.3B) might represent intermediate species in the
aggregation process of ASYN that fail to mature and may,
therefore, lead to proteasomal impairment. To gain insight into
the cellular consequences of different types of ASYN accumulations,
we selected representative mutations for additional studies.
ASYN overexpression and/or aggregation can affect the
secretory pathway. One of the consequences observed is the
disruption of the Golgi and impairment ER-to-Golgi trafficking.
Fragmentation of this organelle has been reported in neurode-
generative disorders [51,52], including PD [53], and it was shown
that it occurs in the cells accumulating prefibrillar ASYN
aggregates [66]. Indeed, we observed the same trend in our study,
where increased Golgi fragmentation was observed in the
oligomerization model, particularly with E35K and E57K ASYN.
Furthermore, we observed increased levels of BiP with familial
mutants of ASYN in the oligomerization model. This was not
detected in the aggregation model, further supporting the concept
that oligomers are detrimental and disturb proteostasis by affecting
the normal intracellular trafficking.
Autophagy is a catabolic process that is involved in the control
of cellular damage in response to genetic perturbations, aging,
and/or environmental toxins. Our study also underscores the
interplay between ASYN inclusion formation and autophagy since
we found the lysosomal marker LAMP-1 surrounding and
concealing mature inclusions, as judged by thioS staining (Fig. 9B).
Again, this reinforces the idea that aggregates per se might not be
directly harmful to cells but, instead, might constitute an effort for
cells to remove abnormal proteins from the cytoplasm.
Altogether, the systematic assessment of the effects of different
ASYN mutations on its oligomerization and aggregation in cellular
models allowed us to address, for the first time, the effect of the
selected mutations on a panel of readouts that reflect important
aspects of the biology/pathobiology of the protein. While additional
studies using alternative models will be important to further dissect
Figure 8. ASYN secretion is inversely correlated with toxicity. A. Secretion of ASYN. B. Toxicity measurements. Medium from H4 cells
were collected to determine the secretion and the percentage cytotoxicity for each mutant. To measure the release of ASYN, an ELISA assay was
performed. Using the same media we also measured the release of lactate dehydrogenase as a measure of cytotoxicity. We observed that these
values were inversely correlated with those obtained in the release/secretion experiments. A decrease trend particularly for TP and Y125F detected in
terms of secretion, was higher in toxicity. n = 3. C. Correlation between Secretion and Toxicity. The graph shows the inverse trend in secretion
and toxicity.
doi:10.1371/journal.pgen.1004741.g008
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the effects of mutations, our study establishes the foundation for
testing hypotheses that may open novel opportunities for the
development of therapeutic strategies for synucleinopathies.
Materials and Methods
Primer design
The primers were designed according to the manufacturer’s
instructions using the QuickChange Primer Design Program and
the web-based program Primer X (Table S1).
Generation of the mutant ASYN constructs
Site-directed mutagenesis using QuickChange II Site-Directed
Mutagenesis Kit (Agilent Technologies, SC, USA) was performed
following the manufacturer’s instructions. Mutagenesis were
performed in the plasmids encoding the ASYN-Venus BiFC
system [42] or SynT [43] and confirmed by DNA sequencing.
Also, fusion constructs ASYN-hGLuc1 (S1) and ASYN-hGLuc2
(S2) were generated as described previously [42].
Yeast plasmids expressing GFP (pME3759), human wild-type
ASYN-GFP (pME3763), A30P-GFP (pME3764), A53T-GFP
(pME3765) and TP-GFP (pME3942) from galactose-inducible
promoter (GAL1) were described previously [67]. Plasmids
harboring E46K-GFP (pME4085), E35K-GFP (pME4086),
E57K-GFP (pME4087) and Y125F-GFP (pME4088) were gener-
ated by site-directed mutagenesis using the same primers as above.
Plasmid pME3763 was used as a template for generation of the
desired amino acid substitutions.
Cell culture
Human neuroglioma cells (H4) were maintained in Opti-MEM
I Reduced Serum Medium (Life Technologies- Gibco, Carlsbad,
Figure 9. ASYN partially co-localizes with endosomes/lysosomes. A. Immunocytochemistry analysis of H4 cells expressing selected
ASYN mutants. Partial co-localization of ASYN and LAMP1 suggests interplay between lysosomal degradation and ASYN inclusion formation. B.
E57K and Y125F inclusions co-localize with lysosomal marker LAMP-1. We detected the presence of endosomes/lysosomes surrounding
the aggregates in E57K and Y125F. This indicates that, maybe this could be the preferential via for degradation for these mutations. Scale bar: 10 mm.
doi:10.1371/journal.pgen.1004741.g009
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CA, USA) and Human Embryonic Kidney 293 (HEK) cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM, Life
Technologies- Invitrogen, Carlsbad, CA, USA). Both media were
supplemented with 10% Fetal Bovine Serum Gold (FBS) (PAA,
Co¨lbe, Germany) and 1% Penicillin-Streptomycin (PAN, Aiden-
bach, Germany). The cells were grown at 37uC in an atmosphere
of 5% CO2.
Cell transfection
HEK cells. The cells were plated in 24-well plates (Costar,
Corning, New York, USA) the day before. Thirty minutes before
the transfection the cells were incubated in Opti-MEM (Life
Technologies-Invitrogen, Carlsbad, CA, USA) and subsequently
transfected with equimolar amounts of the plasmids using
Metafectene (Biotex, Munich, Germany) according to the
manufacturer’s instructions. Five hours after transfection, the
medium was replaced. Twenty-four hours after transfection the
cells were collected or stained for further analysis.
H4 cells. Twenty-four hours prior to transfection, the cells
were plated in 35 cm dish (Ibidi, Munich, Germany) or in 12-well
plates (Costar, Corning, New York, USA). Equal amount of the
plasmids encoding ASYN and synphilin-1 were transfected using
FuGENE6 Transfection Reagent (Promega, Madison, USA) in a
ration of 1:3 according to the manufacturer’s instructions. Forty-
eight hours after the transfection, the media were collected and
frozen for further experiments. Additional, cells were subjected to
immunocytochemistry, for studying ASYN inclusions.
Gaussia luciferase protein-fragment complementation
assay
For the bioluminescence complementation assay with ASYN-
hGLuc1 (S1) and ASYN-hGLuc2 (S2) constructs, the cells were
transfected as described above and conditioned media was
collected 48 hours post-transfection and centrifuged for 5 minutes
at 3000 g to eliminate floating cells before being used.
Forty-eight hours after transfection, culture media was trans-
ferred to a new 96 well plate (Costar, Corning, NY, USA). Cells
were washed with PBS and replaced with serum- and phenol-red
free media. Luciferase activity from protein complementation was
measured for conditioned media and live cells in an automated
plate reader at 480 nm with a signal integration time of 2 seconds
following the injection of the cell permeable substrate, Coelenter-
azine (20 mM) (PJK, Kleinblittersdorf, Germany).
Yeast cell culture conditions
Yeast strain W303-1a (MATa; ura3-1; trp1D 2; leu2-3,112;
his3-11,15; ade2-1; can1-100) was used for transformation
performed by standard lithium acetate protocol. All strains were
grown in Synthetic Complete medium lacking uracil (SC-Ura),
supplemented with 2% raffinose or 2% galactose. ASYN
expression was induced by shifting yeast cells cultured overnight
in raffinose to galactose medium (OD600 = 0.1).
Overnight cultures of yeast strains were grown in SC-Ura
medium containing 2% raffinose. For induction of the GAL1
promoter, cells were inoculated in SC-Ura medium containing 2%
Figure 10. A-B morphology analysis of Golgi apparatus. The morphology of the Golgi apparatus in.50 cells was analysed and quantified. We
observed that, in the BiFC assay, E35K and E57K mutants displayed increased Golgi fragmentation (A). In the aggregation model, Golgi morphology
appeared normal, displaying a compact appearance near the nucleus (B). Levels of BiP in the oligomerization assay (C) and in the
aggregation model (E), assessed by immunoblot analysis and respective quantifications (D and E). n = 3. Student’s t test (*p,0.05, **p,
0.01, ***p,0.001).
doi:10.1371/journal.pgen.1004741.g010
Figure 11. Correlation between the effects of ASYN mutations on oligomerization and inclusion formation. The graph depicts how
mutations affect oligomerization and inclusion formation, enabling the selection of mutants with different effects. Values were attributed to ASYN
mutations according to the results from the two models (oligomerization and inclusion formation) using WT ASYN as reference (center of the graph).
doi:10.1371/journal.pgen.1004741.g011
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galactose to an OD600 =0.1 and incubated for 6 h. Cell extracts
were prepared and the protein concentrations were determined
with a Bradford assay. Immunoblotting was performed following
standard procedures using anti-ASYN monoclonal antibody
(AnaSpec, CA, USA) or Cdc28 polyclonal antibody (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) as a loading control.
Spotting assays
To analyse cell growth on solid media, cultures were grown to
mid-log phase in SC-Ura medium containing raffinose. Cells were
normalized to equal densities, serially diluted 10-fold starting with
an OD600 of 0.1, and spotted on SC-Ura plates containing either
2% glucose or 2% galactose. After 3 days incubation at 30uC the
plates were photographed.
Fluorescence microscopy and quantifications of yeast
cells
Yeast cell cultures were grown in SC-Ura medium containing
2% raffinose until mid-log phase and transferred to SC-Ura
medium supplemented with 2% galactose. Expression was induced
for 6 h and fluorescent images were obtained with Zeiss Observer.
Z1 microscope equipped with CSU-X1 A1 confocal scanner unit
(YOKOGAWA), QuantEM:512SC (Photometrics) digital camera
and SlideBook 5.0 software package (Intelligent Imaging Innova-
tions). For quantification of aggregation at least 300 cells were
counted per strain and per experiment. For each strain, the
number of cells displaying cytoplasmic foci was reported to the
total number of cells counted and displayed as percentage on a
column chart.
Immunocytochemistry
Twenty-four or forty-eight hours after transfection, cells (HEK
or H4) were washed with PBS and fixed with 4% paraformal-
dehyde (PFA) for 10 minutes at room temperature (RT), followed
by a permeabilization step with 0.5% Triton X-100 (Sigma-
Aldrich, St. Louis, MO, USA) for 20 minutes at RT. After
blocking in 1.5% normal goat serum (PAA, Co¨lbe, Germany)/
DPBS for 1 hour, cells were incubated with primary antibody.
Primary antibodies used were: mouse anti-ASYN (1:1000, BD
Transduction Laboratory, New Jersey, USA) or rabbit anti-
ASYN (1:1000, Abcam, Boston, USA), rabbit anti-LAMP-1
(1:1000, Abcam, Boston, USA), anti-Giantin (1:1000, Abcam,
Boston, USA) for 3 hours or overnight and secondary antibody
(Alexa Fluor 488 donkey anti-mouse IgG and/or Alexa Fluor 555
goat anti rabbit IgG, (Life Technologies- Invitrogen, Carlsbad,
CA, USA) for 2 hours at RT. Finally, cells were stained with
Hoechst 33258 (Life Technologies- Invitrogen, Carlsbad, CA,
USA) (1:5000 in DPBS) for 5 minutes, and maintained in PBS for
epifluorescence microscopy.
STED microscopy
For STED microscopy, H4 cells were plated in 15 mm
coverslips. Forty-eight hours after transfection, the cells were
washed with PBS and fixed with 4% PFA for 30 minutes at RT.
The cells were rinse with quenching buffer (PBS +100 mM of
Ammonium Chloride (Sigma-Aldrich, St. Louis, MO, USA)) for
15 minutes. After washing, the cells were permeabilized and
blocked (2% BSA and 0.1% Triton X-100, in PBS) for 20
minutes. Cells were then incubated with primary antibodies
against ASYN (1:2000, BD Transduction Laboratory, New
Jersey, USA) in the permeabilization-blocking solution diluted
1:2 with PBS for 1 hour at RT. Finally, we incubated the cells
with a secondary goat anti-mouse antibody labeled with Atto
647N (5 mg/mL; Sigma-Aldrich, St. Louis, MO, USA). STED
images were taken with a Leica TCS STED system (Leica
Microsystems) with a 100X oil objective (1.4 numerical aperture,
NA, 1003 HCX PL APO CS oil; Leica Microsystems). For
excitation, we used a 635 nm diode laser, and for the depletion
donut (130 mW with the 1003 objective) we used a Spectra-
Physics MaiTai multiphoton laser at 750 nm (Newport Spec- tra-
Physics). Scans were performed at 1,000 Hz and the final images
represent an average of 96 scans (STED) (average performed line-
by-line) with the pinhole set at 47 mm. STED images were
obtained at 20.20620.20 nm pixels.
Thioflavin S staining
After staining with secondary antibody, cells were incubated
with freshly prepared 0.05% Thioflavin S (Sigma-Aldrich, St.
Louis, MO, USA) for 5 minutes. Cells were then washed with 80%
EtOH for 5 minutes and, finally, stained with Hoechst 33258,
washed and maintained in PBS for fluorescence microscopy.
Quantification of nuclear and cytoplasmic fluorescence
intensities
Nuclear and cytoplasmic fluorescence intensities were quanti-
fied using ImageJ software (http://rsbweb.nih.gov/ij/). Using the
freehand tool the nucleus and cytosol were selected and the
respective intensities were measured. The results reflect the
counting of 25 cells per experiment.
Quantification of ASYN inclusions
Transfected cells were detected and scored based on the ASYN
inclusions pattern and classified into four groups: cells without
inclusions, less than five inclusions (,5 inclusions), between five to
nine inclusions ($5–9 inclusions) and more than ten inclusions ($
10 inclusions). Results were expressed as the percentage of the
total number of transfected cells obtained from three independent
experiments for each mutation.
Quantification of Golgi fragmentation
Transfected HEK and H4 cells were scored based on the
morphology of the Golgi apparatus and classified into three
groups: non-fragmented, diffused and fragmented. Results were
expressed as the percentage of the total number of transfected
cells. Three independent experiments were performed.
Western blot analyses
HEK and H4 cells were lysed with Radio-Immunoprecipitation
Assay (RIPA) lysis buffer (50 mM Tris pH 8.0, 0.15 M NaCl,
0.1% SDS, 1% NP40, 0.5% Na-Deoxycholate), 2 mM EDTA and
a Protease Inhibitor Cocktail (1 tablet/10 mL) (Roche Diagnostics,
Mannheim, Germany). To detect phosphorylated-ASYN was
added Phosphatase Inhibitor Cocktail (1 tablets/10 mL) (Roche
Diagnostics, Mannheim, Germany). Protein concentration was
determined using the Bradford assay (BioRad Laboratories,
Hercules, CA, USA) and the gels were loaded with 40 mg protein
after denaturation for 10 minutes at 100uC in protein sample
buffer (125 mM of 1 M Tris HCl pH 6.8, 4% SDS 0,5%
Bromphenol blue, 4 mM EDTA 20% Glycerol 10% b-Mercapto
ethanol).
The samples were separated on 12% SDS-polyacrylamide gels
(SDS-PAGE) with a constant voltage of 110 V using Tris-Glycine
SDS 0.5% running buffer (250 mM Tris, 200 mM Glycin, 1%
SDS, pH 8.3) for 60 minutes.
The transfer was carried out to nitrocellulose membrane
(Protran, Schleicher and Schuell, Whatman GmbH, Dassel,
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Germany) for 90 minutes with constant current at 0.3 A using
Tris-Glycine transfer buffer.
Membranes were blocked with 5% (w/v) skim milk (Fluka,
Sigma-Aldrich, St. Louis, MO, USA) in 1xTBS-Tween (50 mM
Tris, 150 mM NaCl, 0.05% Tween, pH 7.5) for 60 minutes at
RT.
Membranes were further incubated with the primary antibody,
either mouse anti-ASYN (1:1000, BD Biosciences, San Jose, CA,
USA) or rabbit anti-ASYN (1:1000, Santa Cruz Biotechnologies,
Santa Cruz, CA, US), anti-BiP (BD Biosciences, San Jose, CA,
USA) and 1:1000 mouse anti-b-actin (Sigma-Aldrich, St. Louis,
MO, USA) in 3% Albumin Bovine Fraction V (BSA)/TBS-Tween
(NZYTech, Lisbon, Portugal), at RT for 3 hours or overnight at
4uC.
After washing three times in TBS-Tween for five minutes, the
membranes were incubated for 1 hour with secondary antibody,
anti-mouse IgG, or anti-rabbit IgG, horseradish peroxidase
labeled secondary antibody (GE Healthcare, Bucks, UK) at
1:10000 in 3% milk/TBS-Tween.
Detection was done using Luminol Reagent and Peroxide
Solution (Millipore, Billerica, MA, USA) and applied to the
membrane 1 minute before scanning with in AlphaImager
FluoroChem software (AlphaInnotech).
Protein levels were quantified using ImageJ and normalized to
the b-actin levels.
H4 cells transfected with ASYN-hGLuc constructs were washed
with cold PBS to remove excess cell culture media. Cell lysis buffer
(20 mM NaCl, 0,6% Deoxycholate, 0,6% Igepal, 25 mM Tris
pH 8.0, Protease Inhibitor Cocktail tablet, 1 tablet/10 mL) was
added on human H4 cells in 60 mm dishes and incubated on ice
for 10 minutes. After cell scraping samples were centrifuged for 10
minutes at 13,000 g. Lysates were resolved by electrophoresis on a
4–12% Bis-Tris gradient gel (NuPAGE Novex Bis-Tris Gel, Life
Technologies, Darmstadt, Germany) according to manufacturer’s
instructions using NuPAGE MOPS buffer. After transfer to
nitrocellulose membrane (Protran, Schleicher and Schuell, What-
man GmbH, Dassel, Germany) membranes were blocked in 1x
Roti Block (Roth, Carlsbad, Germany) for 1 hour at RT. The
forward steps were similar as describe above.
Assessment of ASYN phosphorylation
The blots were directly removed from the blotting chamber and
fixed in 0.4% PFA in PBS for 30 minutes. The membranes were
briefly boiled in PBS, washed very short in TBS-Tween with
phosphatase inhibitor (25 mM B-Glycerolphosphat, 5 mM NaF,
1 mM Na3VO4), and then were blocked in 5% BSA/TBS-Tween
with phosphatase inhibitor for at least 1 hour (in the cold room).
Anti-S129 phosphorylation ASYN 1:1000, WAKO, Richmond,
Virginia, USA) was prepared in 5% BSA/TBS-Tween with
phosphatase inhibitor and incubated overnight in the cold room.
After washing tree times with TBS-Tween with phosphatase
inhibitor for 10 minutes, the membranes were incubated with
secondary antibody (anti-mouse IgG) for 1,5 hours at RT. Finally
they were washed and revealed as previously described.
Native PAGE
For native PAGE, samples were lysed with detergent-free lysis
buffer (50 mM Tris HCl pH 7.4, 175 mM NaCl, 5 mM EDTA
pH 8.0 and Protease Inhibitor Cocktail tablet, 1 tablet/10 mL).
Native-PAGE was run with detergent-free Tris-Glycine running
buffer (250 mM Tris and 200 mM Glycin) and in protein sample
buffer (1 M Tris HCl pH 6.8, Glycerol 100%, 0,4% Bromophenol
blue).
Detergent solubility experiments
The H4 cells were plated and transfected as previously describe.
Using 80 mL lysing buffer 1 (25 mM Tris pH 7.5, 150 mM NaCl,
1 mM EDTA, 1% Triton X-100, K tablet of EDTA Protease
Inhibitor) the cells were harvested and centrifuged at 100.000 g for
30 minutes at 4uC. Supernatants were collected (soluble fraction)
and the pellets (insoluble fraction) were washed with cold PBS and
transferred to new tubes.
Once again, the samples were centrifuged at 14.000 rpm for 10
minutes at 4uC and the pellets were resuspended in 50 mL lysing
buffer 2 (75 mM Tris pH 6.8, 3% SDS, 15% Glycerin, 3.75 mM
EDTA pH 7.4). Finally, the samples were sonicated (10 pulse/
second) and a western blot was run as previously described.
The insoluble fraction was calculated as:
insoluble fraction
insoluble fractionz soluble fraction
and then normalized for
ASYN WT.
Flow cytometry
HEK cells were plated and imaged after twenty-four hours, as
described above. Then, cells were trypsinized, neutralized with
growth medium, centrifuged (1500 g at 5uC) and the pellet was
reconstituted in 7-aminoactinomycin D (7-AAD, Life Technolo-
gies- Invitrogen, Carlsbad, CA, USA) prepared 1:1000 in PBS.
The fluorescence was measured using a microcapillary system
(GuavaeasyCyte HT system, Millipore). 25000 events were
counted per sample.
ASYN levels in the culture medium
A detailed description of the assay procedure has been
published before [50]. [50]96-well Multi-Array standard plates
(Meso Scale Discovery, Gaithersburg, MD, USA) were coated
with 30 ml of MJF1 clone 12.1 (kindly provided by Liyu Wu,
Epitomics, Burlingame, CA, USA) as capture antibodies at 3 mg/
ml dissolved in PBS buffer and incubated overnight at 4uC without
shaking. All washing steps were done three times with 150 ml PBS-
T (PBS supplemented with 0.05% Tween-20). After washing away
the capture antibodies plates were blocked with 1% BSA/PBS-T
for 1 h at RT with shaking at 300 rpm. Standards and biosamples
collected from H4 cells were diluted in 1% BSA/PBS-T and
applied in 25 ml volumes. Incubation was done for 1 h (RT,
700 rpm). Plates were washed again and 25 ml Sulfo-TAG labelled
ASYN (BD Biosciences, Heidelberg, Germany) were applied at
1 mg/ml. After a final washing 150 ml 2x Read Buffer T (MSD)
were applied to the wells and plates were read in a Sector Imager
6000 (MSD).
Toxicity assays – LDH release
For lactate dehydrogenase (LDH) cytotoxicity assay (Roche
Diagnostics, Mannheim, Germany) the reaction mixture were
prepared according to the manufacturer. The growth media from
H4 cells were plated in triplicates in a 96 well plate, in a ratio 1:1
with the reaction mixture. The absorbance measurements were
performed in a TECAN Infinite 200 Pro plate reader at 490 nm.
To determine the percentage cytotoxicity, the average absorbance
values were subtracted with the average absorbance value
obtained in the background control. The percentage of toxicity
was calculated as indicated by the manufacturer.
Statistical analyses
Data were analysed using GraphPad Prism 5 (San Diego
California, USA) software and were expressed as the mean 6
SEM of at least three independent experiments. The values of
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ASYN mutations from flow cytometry were normalized to WT
ASYN and mean values for each experiment were determined.
Statistical differences from WT ASYN were calculated using
unpaired Student t-test. Significance was assessed for p#0.05,
where * corresponds to p#0.05, ** corresponds to p#0.01 and ***
corresponds to p#0.001.
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Figure S2 Morphological analysis of Golgi apparatus. A.
Oligomerization paradigm B. Aggregation model paradigm.
Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n = 3.
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